Hereditary Spastic Paraparesis Clinical Trial
Official title:
Phase 2 Pharmacological Trial to Evaluate the Safety of Miglustat Administration in Subjects With Spastic Paraplegia 11 (TreatSPG11)
Hereditary spastic paraparesis type 11 (SPG11) is caused by mutations in the SPG11 gene that produces spatacsin, a protein involved in lysosomal function. Studies performed in skin cells (fibroblasts) from SPG11 patients, mice and zebrafish models of the disease showed that the material accumulated in the lysosomes is made of glycosphingolipids (GSL). Miglustat is a drug that inhibits an enzyme called glucosylceramide synthetase (GCS) which is used for the production of GSL. Miglustat, therefore, helps to delay the production of GSL. This study aims to collect preliminary data on the safety of miglustat on the SPG11 disease and to assess biomarkers.
We will analyze the safety of Miglustat ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04256681 -
SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP)
|
N/A | |
| Recruiting |
NCT06229626 -
Evaluation of an Intensive Training Program for Patients With Hereditary Spastic Paraparesis SPG4/Spast
|
N/A | |
| Completed |
NCT00677768 -
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
|
N/A |